[go: up one dir, main page]

CO5241355A1 - PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS - Google Patents

PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS

Info

Publication number
CO5241355A1
CO5241355A1 CO00001261A CO00001261A CO5241355A1 CO 5241355 A1 CO5241355 A1 CO 5241355A1 CO 00001261 A CO00001261 A CO 00001261A CO 00001261 A CO00001261 A CO 00001261A CO 5241355 A1 CO5241355 A1 CO 5241355A1
Authority
CO
Colombia
Prior art keywords
active
packaged form
hepatitis
nucleosidic
against hepatitis
Prior art date
Application number
CO00001261A
Other languages
Spanish (es)
Inventor
Gillian Frances Atkinson
Ronald James Boon
G Vandepapelie Pierre
Anne Cecile Wettendorf Martine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO5241355A1 publication Critical patent/CO5241355A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forma envasada para una composición farmacéutica que comprende como ingredientes activos: (1) un agente antiviral activo contra el virus de la hepatitis B (2) una vacuna para profilaxis y tratamiento de la hepatitis B, dichos ingredientes de uso simultáneo o secuencial. 1Forma envasada para composición farmacéutica para el tratamiento de pacientes con virus de hepatitis B, dicha composición siendo administrada en forma simultánea o secuencial en cualquier orden de un agente antiviral activo contra el virus de hepatitis B y una vacuna contra la hepatitis B, dichos ingredientes en cantidad segura y eficaz.Packaged form for a pharmaceutical composition comprising as active ingredients: (1) an active antiviral agent against hepatitis B virus (2) a vaccine for prophylaxis and treatment of hepatitis B, said ingredients for simultaneous or sequential use. 1 Packaged form for pharmaceutical composition for the treatment of patients with hepatitis B virus, said composition being administered simultaneously or sequentially in any order of an active antiviral agent against hepatitis B virus and a hepatitis B vaccine, said ingredients in safe and effective amount.

CO00001261A 1999-01-12 2000-01-12 PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS CO5241355A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12

Publications (1)

Publication Number Publication Date
CO5241355A1 true CO5241355A1 (en) 2003-01-31

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00001261A CO5241355A1 (en) 1999-01-12 2000-01-12 PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS

Country Status (19)

Country Link
EP (1) EP1140163A2 (en)
JP (1) JP2002534438A (en)
KR (1) KR20010090011A (en)
CN (1) CN1391482A (en)
AR (1) AR022250A1 (en)
AU (1) AU760574B2 (en)
BR (1) BR9916893A (en)
CA (1) CA2359110A1 (en)
CO (1) CO5241355A1 (en)
CZ (1) CZ20012544A3 (en)
HK (1) HK1041434A1 (en)
HU (1) HUP0105070A2 (en)
IL (1) IL144186A0 (en)
NO (1) NO20013337L (en)
NZ (1) NZ512890A (en)
PL (1) PL349347A1 (en)
TR (1) TR200102024T2 (en)
WO (1) WO2000041463A2 (en)
ZA (1) ZA200105690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910643A (en) 1998-05-22 2001-10-30 Loeb Health Res Inst At The Ot Processes and products for inducing mucosal immunity
CN102198266A (en) 1998-07-31 2011-09-28 株式会社国际癌症免疫研究所 Cancer antigens based on tumor suppressor gene WT1 product
CN1281625C (en) 2001-03-22 2006-10-25 株式会社癌免疫研究所 WT1 modified peptide
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
ATE544466T1 (en) 2002-10-29 2012-02-15 Coley Pharm Group Inc USE OF CPG OLIGONUCLEOTIDES TO TREAT HEPATITIS C VIRUS INFECTION
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5' cpg nucleic acids and methods of use
CN100443117C (en) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 Hepatitis B treating vaccine prepn and its prepn process and use
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
AR065504A1 (en) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech COMBINED THERAPY FOR THE TREATMENT OF CHRONIC HEPATITIS B. USE.
WO2020134682A1 (en) * 2018-12-24 2020-07-02 南京远大赛威信生物医药有限公司 Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
JPWO2022215737A1 (en) * 2021-04-07 2022-10-13

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0414374T3 (en) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog New antigens and methods for their preparation
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions

Also Published As

Publication number Publication date
ZA200105690B (en) 2002-09-25
WO2000041463A3 (en) 2000-11-09
AU2100900A (en) 2000-08-01
NO20013337D0 (en) 2001-07-05
WO2000041463A2 (en) 2000-07-20
AU760574B2 (en) 2003-05-15
TR200102024T2 (en) 2001-12-21
CN1391482A (en) 2003-01-15
PL349347A1 (en) 2002-07-15
BR9916893A (en) 2001-11-20
EP1140163A2 (en) 2001-10-10
CA2359110A1 (en) 2000-07-20
IL144186A0 (en) 2002-05-23
HK1041434A1 (en) 2002-07-12
AR022250A1 (en) 2002-09-04
CZ20012544A3 (en) 2002-01-16
NO20013337L (en) 2001-08-17
KR20010090011A (en) 2001-10-17
JP2002534438A (en) 2002-10-15
NZ512890A (en) 2003-09-26
HUP0105070A2 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
AR029655A1 (en) IMPROVEMENTS IN FORMULATIONS IN PASTA
BR0108435A (en) Formulation and use of low dose entecavir
AR018410A1 (en) USE OF A COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT USED FOR THE PREVENTION OR TREATMENT OF AN ACUTE STATE OF ASTHMA AND / OR ASTHMA INTERMITENTEY / OR EPISODES OF CHRONIC ASTHMA AND METHOD FOR THE PREVENTION OR TREATMENT OF AN ACUTE STATE OF ASTHMA AND / OR INTERMITTENT ASTHMA AND / OR ASTHON CRON EPISODES
CO5241355A1 (en) PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
BR0107869A (en) Electrogenated pharmaceutical compositions
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
MX9202407A (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT AND PROCESS FOR ITS PREPARATION.
BR0008590A (en) Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed
ECSP045102A (en) Pharmaceutical formulation containing 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and provides a delayed release of the active ingredient
AR005281A1 (en) ORAL PHARACEUTICAL COMPOSITION, PROCEDURES FOR ITS MANUFACTURE AND USE OF THAT PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF MEDICINES. .
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
AR033688A1 (en) RECONSTITUABLE PARENTERAL COMPOSITION
ES2160163T3 (en) PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE CLASS OF TAXANOS.
AR026254A1 (en) THE USE OF A CONTROLLED RELEASE PREPARATION FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INCREASE THE DOSE OR SYSTEM EXPOSURE OF A PHARMACO THAT INHIBITS PHOSPHODESTERASE 4
AR045263A1 (en) METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.
CA2385755A1 (en) Prevention of colorectal cancer
UY26514A1 (en) "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES".
UY26595A1 (en) LOW DOSE USE USE FORMULATIONS
ECSP003685A (en) ORAL FORMULATIONS OF CONTROLLED RELEASE
AR027287A1 (en) GONADOTROPHIN
BR0212744A (en) Cisplatin formulations of reduced toxicity and methods for their use
CO5271647A1 (en) METHOD TO PREVENT DIARRHEA

Legal Events

Date Code Title Description
FC Application refused